# Research Peptide Fundamentals > Research Peptide Fundamentals research peptides | Peptides Health — Research Peptide Fundamentals research peptides, audited across semaglutide, NAD+, BPC-157 and PT-141 by an independent evidence desk. **EVIDENCE AUDIT / DESK 01** Four compounds. Four very different evidence bases. One disciplined reading of what peptide health research can and cannot support. ### [Semaglutide](/semaglutide) Large human trials, defined metabolic endpoints and a mature safety record make this the benchmark in the audit. ### [NAD+](/nad) A central cellular coenzyme with clear biomarker effects from precursors, but limited proof for broad longevity claims. ### [BPC-157](/bpc-157) A repair-focused research peptide whose reputation reaches much further than its small human evidence base. ### [PT-141](/pt-141) A central melanocortin agonist with an approved identity, defined population and controlled trial program. ## The short version Peptide health claims often arrive in the same language: repair, energy, appetite, longevity or sexual function. The evidence behind those words is not equally strong. This desk examines four widely discussed compounds and asks a simple set of questions. Was the result seen in people, animals or cells? Did the study measure a health outcome, a laboratory marker or a feeling reported by participants? Does the claim stay within the population that was studied? Semaglutide has large controlled trials tied to weight, cardiovascular and kidney outcomes. NAD+ research often shows that a precursor can raise a blood marker, while broader anti-ageing promises remain unsettled. BPC-157 has extensive animal work but almost no dependable human efficacy evidence. PT-141, also called bremelanotide, has controlled human studies for a narrow indication. Reading those records side by side shows why the label “peptide” says little about evidence quality. ## Four claims, four standards of proof Peptides Health treats every health claim as a chain of evidence. The first link is the intervention itself: a prescribed peptide medicine, an endogenous molecule, a nutrient precursor or an experimental research compound. The next link is the model. A randomized human trial can answer a different question from a rodent injury model, a cell experiment or a community review. The final link is the endpoint: what investigators actually measured. The distinctions matter here. Semaglutide trials measured body weight and major clinical events in large groups [2][3][4]. NAD+ precursor studies measured blood NAD+ and selected functional or metabolic outcomes, yet the current review literature still describes human efficacy as limited [8][9][10][12]. BPC-157 research includes vascular signaling and ulcer healing in laboratory models, while a recent review found only a very small human pilot literature [13][14][16][17]. Bremelanotide trials used validated desire and distress measures in a defined clinical population [19][20][21]. A result is not discarded because it is early. It is placed at the right level. Mechanistic evidence can explain plausibility. Animal evidence can justify further study. A biomarker can show biological activity. None automatically proves a broad health benefit. ## What “research peptide” means at this desk The term covers chemically and legally different things. Semaglutide is a peptide-based prescription medicine that activates the GLP-1 receptor. PT-141 is the research name commonly attached to bremelanotide, another approved prescription medicine, but one aimed at central melanocortin signaling rather than metabolic incretin signaling. BPC-157 is an experimental peptide without an approved therapeutic indication. NAD+ is different again: it is an endogenous coenzyme rather than a peptide, but it appears in the same health-optimization conversation through precursor supplements and compounded wellness services. That mixed roster is useful because it exposes a common reasoning error: carrying confidence from a well-studied member of a category over to every other member. Approval, controlled trials and validated endpoints belong to a specific compound, formulation, population and claim. They do not transfer by association. The [comparison desk](/compare) keeps those boundaries visible. ## Endpoints, surrogates and unsupported extensions A clinical endpoint records something that directly matters to health or function. A surrogate is an indirect measure used as a stand-in, such as a blood concentration, imaging feature or signaling response. Surrogates can be valuable, but they need validation before they can carry a larger promise. Semaglutide offers examples of both direct and intermediate evidence. Trials have recorded major cardiovascular and kidney outcomes, not only laboratory changes [2][3]. NAD+ precursor trials reliably show movement in the NAD+ pool, but a higher circulating level does not itself establish longer life or broad disease prevention [8][12]. BPC-157 can activate a vessel-growth pathway in experimental systems [16]; that mechanism does not establish faster recovery in people. PT-141 changed brain processing and improved trial measures of desire and distress in the population studied [19][20], while extensions to other groups remain outside that evidence. The audit therefore uses verbs carefully. A trial “found” an endpoint. A model “suggests” a mechanism. A biomarker “changed.” A community “reports” an experience. These are not stylistic preferences; they preserve what the source can actually bear. ## How to use this reference desk Each compound page begins with a plain-language orientation, then moves through identity, mechanism, findings, reported experience and safety. Numbered citations lead to a shared [reference index](/references). Study size, duration and effect estimates appear only with the source that supports them. The editorial rule is conservative: the strongest claim on a page should never be stronger than its strongest relevant source. Community reports are presented only as **anecdotal, not clinical evidence**. Safety sections distinguish observed adverse events from theoretical concerns. The site does not convert study protocols into instructions, and it does not infer personal decisions from population-level evidence. Start with [semaglutide](/semaglutide) for the most mature clinical record, or move directly to [NAD+](/nad), [BPC-157](/bpc-157) or [PT-141](/pt-141). The contrast between them is the point: health claims become more useful when their evidence level is visible. --- Peptides Health independently audits peptide health claims against their studied endpoints, and serves as a literature digest rather than a clinic, shop or source of medical advice.